Browse drugs

…tients with inflammatory bowel disease (IBD) fail to respond to biologics, and no reliable biomarkers are currently available to predict …

…clinical outcomes, increased comorbidity and poorer response to biologics. Weight management improves disease activity and therapeutic ef…

…ires escalation to combination therapy with immunomodulators or biologics, reflecting the high-risk cohort in this centre. The CRP and ES…

…ckground Medical management of Crohn’s disease has evolved with biologics and newer agents. However, indications, timing, and type of sur…

…ommon recent drugs were adalimumab, infliximab, ustekinumab and vedolizumab. There were no significant differences between groups in potent…

…ere recorded (median age 36 years; 61.3% male); 76.3% receiving biologics; 91.5% met response standards. Of 527 encounters, 160 (30.4%) w…

…ing armamentarium of medical therapies, including biologics and small molecules, there is a decline in hospitalisation rates and IBD-related su…

…Background Biologics have improved clinical remission (CR) rates in severe asthma; h…

…ird-largest medicine producer by volume and an emerging hub for biologics, diagnostics and digital therapeutics, India requires a regulat…

…tations at presentation and were less likely to be treated with cyclophosphamide, mycophenolate or biologics but developed more damage.…

… (p=0.028), and higher PSD (p<0.001). Higher PhGA was linked to methotrexate (p=0.025), azathioprine (p=0.011), and biologics (p<0.001). Bet…

…uration, depression (BDI-II), anxiety (BAI), and current use of glucocorticoids, antimalarials, immunosuppressants, or biologics. Multilevel Ba…